News & Updates

Show Multimedia Only

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

The oral, selective factor D inhibitor vemircopan has shown no evidence of benefit in the treatment of adult patients with acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis in a phase 2 trial.

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

10 hours ago

Satralizumab cuts relapse risk in MOGAD

21 hours ago by

Satralizumab reduces the risk of relapse by 68 percent in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), as shown in the phase III METEOROID study presented at AAN 2026.

Satralizumab cuts relapse risk in MOGAD

21 hours ago

Insomnia with short sleep duration linked to cardiovascular, cerebrovascular disease

14 Jun 2026

Individuals with insomnia with short sleep duration are at heightened risk of cardiovascular disease (CVD) and cerebrovascular disease (CBVD), according to a study.

Insomnia with short sleep duration linked to cardiovascular, cerebrovascular disease

14 Jun 2026

Brain-derived p-tau217 highly accurate for detecting amyloid burden in older Asian adults

13 Jun 2026 by

Local research has shown measuring brain-derived p-tau217 in blood has superior accuracy than measuring other p-tau species for detecting Alzheimer’s disease (AD)-related amyloid pathology in older adults in Singapore.

Brain-derived p-tau217 highly accurate for detecting amyloid burden in older Asian adults

13 Jun 2026

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

13 Jun 2026

The use of low-dose rivaroxaban among patients with advanced chronic kidney disease (CKD) and high cardiovascular (CV) risk does little to reduce the risk of adverse CV events and may even contribute to increased bleeding events, according to the TRACK randomized clinical trial.

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

13 Jun 2026

Adverse reproductive factors plus unhealthy lifestyle tied to higher risk of cognitive decline

09 Jun 2026

In Chinese postmenopausal women, adverse reproductive factors combined with unhealthy lifestyle behaviours appear to be associated with increased likelihood of cognitive decline, as reported in a study.

Adverse reproductive factors plus unhealthy lifestyle tied to higher risk of cognitive decline

09 Jun 2026

Oral semaglutide provides limited benefit in individuals with early AD

09 Jun 2026

The use of oral semaglutide does not reduce the speed of clinical progression in individuals with early Alzheimer's disease (AD), according to the results to two phase III trials.

Oral semaglutide provides limited benefit in individuals with early AD

09 Jun 2026

High choline, betaine intakes may improve cognitive performance in older adults with obesity

08 Jun 2026 by

Regular intake of dietary choline and betaine results in moderate short-term improvements in cognitive function and helps prevent cognitive decline in older adults with overweight or obesity and metabolic syndrome (MetS), reveals a study.

High choline, betaine intakes may improve cognitive performance in older adults with obesity

08 Jun 2026

Electroacupuncture a potential nonpharmacologic option for managing postherpetic neuralgia

08 Jun 2026

In the management of patients with postherpetic neuralgia, electroacupuncture helps relieve pain and improve pain-related functional outcomes, according to a study.

Electroacupuncture a potential nonpharmacologic option for managing postherpetic neuralgia

08 Jun 2026

Ecopipam halves relapse risk in paediatric Tourette syndrome

06 Jun 2026 by

The phase 3 trial of the selective dopamine D1 receptor antagonist ecopipam has demonstrated maintenace of tic suppression for up to 24 weeks and reduction in the risk of relapse of 50 percent in children with Tourette syndrome.

Ecopipam halves relapse risk in paediatric Tourette syndrome

06 Jun 2026

News & Updates

Showing Neurology articles

Showing

Specialty:

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Satralizumab cuts relapse risk in MOGAD

Satralizumab cuts relapse risk in MOGAD

Insomnia with short sleep duration linked to cardiovascular, cerebrovascular disease

Insomnia with short sleep duration linked to cardiovascular, cerebrovascular disease

Brain-derived p-tau217 highly accurate for detecting amyloid burden in older Asian adults

Brain-derived p-tau217 highly accurate for detecting amyloid burden in older Asian adults

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

Low-dose rivaroxaban more harmful than beneficial in advanced CKD patients at high CV risk

Adverse reproductive factors plus unhealthy lifestyle tied to higher risk of cognitive decline

Adverse reproductive factors plus unhealthy lifestyle tied to higher risk of cognitive decline

Oral semaglutide provides limited benefit in individuals with early AD

Oral semaglutide provides limited benefit in individuals with early AD

High choline, betaine intakes may improve cognitive performance in older adults with obesity

High choline, betaine intakes may improve cognitive performance in older adults with obesity

Electroacupuncture a potential nonpharmacologic option for managing postherpetic neuralgia

Electroacupuncture a potential nonpharmacologic option for managing postherpetic neuralgia

Ecopipam halves relapse risk in paediatric Tourette syndrome

Ecopipam halves relapse risk in paediatric Tourette syndrome